Imvax Advances a New Approach to Personalized Cancer Immunotherapy
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
**Sponsored Content**
An acoustic neuroma diagnosis comes with complex treatment decisions. Read why a multidisciplinary care team is crucial for your long-term recovery.
With the reigniting of the White House’s Cancer Moonshot Initiative, the ABTA recently joined the Brain Cancers Forum in Washington, D.C., to discuss opportunities in discovering treatments for brain cancers, including GBM.
David Hou is awarded for his research on leveraging a B cell vaccine to improve immunotherapy treatment for GBM.
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
Meet two researchers on opposite ends of the globe dedicated to transforming the future of brain tumor treatments.
Dr. Duane Mitchell, MD, PhD, Univ. of Florida, shares four highlights in recent GBM research and what he’s hopeful for in the future.
Read three takeaways from the American Association for Cancer Research annual meeting in April.
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631
